10-K - Jaguar Uranium Corp. (0002039273) (Filer) March 27, 2026 4:30 pm | NYSE Jaguar Uranium Corp. 2025 Annual Report: Key Investor Insigh...
Jaguar Health Announces Stockholder Approval of All Proposals at April 2026 Special Meeting April 21, 2026 Jaguar Health Reports Approval of All Proposals at April 202...
Jaguar Health, Inc. Files Form 8-K with SEC Detailing Company Information and NASDAQ Listing (April 2026) April 10, 2026 Jaguar Health, Inc. Files 8-K: Stockholders' Equity Update a...
Jaguar Health Reports 2025 Financial Results: 5% Q4 Revenue Growth, $16M Up-Front License Deal, and Nasdaq Compliance Appeal 1 April 7, 2026 Jaguar Health, Inc. Reports Q4 2025 Financial Results: Detai...
Jaguar Health, Inc. 2025 Annual Report: Key Financials, Agreements, and Business Segment Highlights April 7, 2026 Jaguar Health, Inc. 2025 Annual 10-K: Key Highlights and Inv...
Jaguar Uranium Corp: Uranium Exploration, Risk Factors, and Regulatory Insights in Argentina and Colombia March 28, 2026 Jaguar Uranium Corp. 2025 Annual Report: Key Investor Insigh...
Jaguar Health, Inc. Enters Global Amendment Agreements and Security Agreement – March 2026 8-K Filing Details March 9, 2026 Jaguar Health, Inc. Announces Significant Amendments to Roya...
Jaguar Health, Inc. 8-K SEC Filing Summary for March 5, 2026 – Company Information, NASDAQ Listing, and XBRL Data March 7, 2026 Jaguar Health, Inc. Receives Nasdaq Delisting Notice After F...
Jaguar Uranium Corp. IPO: Key Insights, Financials, Management, and Investment Risks (2026 S-1/A Filing) February 7, 2026 Jaguar Uranium Corp. IPO Analysis: Comprehensive Investor Gu...
